Limits...
Circulating endothelial-derived apoptotic microparticles in the patients with ischemic symptomatic chronic heart failure: relevance of pro-inflammatory activation and outcomes.

Berezin AE, Kremzer AA, Samura TA, Martovitskaya YV - Int Cardiovasc Res J (2014)

Bottom Line: Besides, P < 0.05 was considered as statistically significant.During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively.The number of circulating EPMs independently predicted all-cause mortality (OR = 1.58; 95% CI = 1.20 - 1.88; P = 0.001), CHF-related death (OR = 1.22; 95% CI: 1.12 - 1.36; P < 0.001), and CHF-related re-hospitalization (OR = 1.20; 95% CI: 1.11 - 1.32; P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: State Medical University, Internal Medicine Department, Zaporozhye, Ukraine.

ABSTRACT

Background: Endothelial-derived apoptotic microparticles (EMPs) play a pivotal role in endothelial dysfunction in hronic Heart Failure (CHF).

Objectives: The present study aimed to evaluate the association between EMPs and pro-inflammatory biomarkers, clinical status, and outcomes in the patients with ischemic CHF.

Patients and methods: This study was conducted on 154 patients with ischemic symptomatic moderate-to-severe CHF on discharge from hospital. The observation period was up to 3 years. Circulating NT-pro-BNP, TNF-alpha, sFas, and sFas ligand were determined at baseline. Flow cytometry analysis was used for quantifying the number of EMPs. All-cause mortality, CHF-related death, and CHD-re-hospitalization rate were examined. The data were analyzed using descriptive statistics, Receive Operation Characteristic Curve (ROC), and logistic regression analysis. Besides, P < 0.05 was considered as statistically significant.

Results: During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively. The results showed a significant difference between the patients with a large number of EMPs (> 0.514 n/mL) and those with a low level of the biomarker (< 0.514 n/mL) regarding their survival. The number of circulating EPMs independently predicted all-cause mortality (OR = 1.58; 95% CI = 1.20 - 1.88; P = 0.001), CHF-related death (OR = 1.22; 95% CI: 1.12 - 1.36; P < 0.001), and CHF-related re-hospitalization (OR = 1.20; 95% CI: 1.11 - 1.32; P < 0.001).

Conclusions: Among the patients with symptoms of CHF, increased number of circulating EMPs was associated with increased 3-year CHF-related death, all-cause mortality, and risk of recurrent hospitalization due to CHF.

No MeSH data available.


Related in: MedlinePlus

Scatterplots Show Association between EMPs Number in Plasma and sFAS (A), TNF-alpha (B), sFAS ligand (C), NT-pro-BNP (D), sFAS/sFAS Ligand Ratio (E), and NYHA Class (F) in Patient Population
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109036&req=5

fig11946: Scatterplots Show Association between EMPs Number in Plasma and sFAS (A), TNF-alpha (B), sFAS ligand (C), NT-pro-BNP (D), sFAS/sFAS Ligand Ratio (E), and NYHA Class (F) in Patient Population

Mentions: The study results indicated a direct relationship between the number of EMPs in plasma and NYHA functional class (r = 0.93, P = 0.001), sFAS/sFASl ratio (r = 0.88, P = 0.001), sFAS (r = 0.856, P = 0.001), TNF-alpha (r = 0.827, P = 0.001), sFASl (r = 0.589, P = 0.001), and NT-pro-BNP (r = 0.689, P = 0.001). Also, a weak association was observed between the number of EMPs and type 2 diabetes mellitus (r = 0.402, P = 0.003), multi-vessel lesion of coronary arteries (r = 0.362, P = 0.001), Е/Аm (r = 0.360, P = 0.001), Е/Em (r = 0.344, P = 0.001), gender (r = 0.318, P < 0.001 for male), and TC (r = 0.313, P = 0.001). On the other hand, an inverse relationship was found between the number of EMPs and LVEF (r = -0.496, P = 0.001) and eGFR (r = -0.408, P = 0.003). Nevertheless, no significant association was observed between the levels of circulating EMPs and fasting plasma glucose, HbA1c, systolic and diastolic BP, premature CAD in family anamnesis, and medications in both cohorts (Figure 1).


Circulating endothelial-derived apoptotic microparticles in the patients with ischemic symptomatic chronic heart failure: relevance of pro-inflammatory activation and outcomes.

Berezin AE, Kremzer AA, Samura TA, Martovitskaya YV - Int Cardiovasc Res J (2014)

Scatterplots Show Association between EMPs Number in Plasma and sFAS (A), TNF-alpha (B), sFAS ligand (C), NT-pro-BNP (D), sFAS/sFAS Ligand Ratio (E), and NYHA Class (F) in Patient Population
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109036&req=5

fig11946: Scatterplots Show Association between EMPs Number in Plasma and sFAS (A), TNF-alpha (B), sFAS ligand (C), NT-pro-BNP (D), sFAS/sFAS Ligand Ratio (E), and NYHA Class (F) in Patient Population
Mentions: The study results indicated a direct relationship between the number of EMPs in plasma and NYHA functional class (r = 0.93, P = 0.001), sFAS/sFASl ratio (r = 0.88, P = 0.001), sFAS (r = 0.856, P = 0.001), TNF-alpha (r = 0.827, P = 0.001), sFASl (r = 0.589, P = 0.001), and NT-pro-BNP (r = 0.689, P = 0.001). Also, a weak association was observed between the number of EMPs and type 2 diabetes mellitus (r = 0.402, P = 0.003), multi-vessel lesion of coronary arteries (r = 0.362, P = 0.001), Е/Аm (r = 0.360, P = 0.001), Е/Em (r = 0.344, P = 0.001), gender (r = 0.318, P < 0.001 for male), and TC (r = 0.313, P = 0.001). On the other hand, an inverse relationship was found between the number of EMPs and LVEF (r = -0.496, P = 0.001) and eGFR (r = -0.408, P = 0.003). Nevertheless, no significant association was observed between the levels of circulating EMPs and fasting plasma glucose, HbA1c, systolic and diastolic BP, premature CAD in family anamnesis, and medications in both cohorts (Figure 1).

Bottom Line: Besides, P < 0.05 was considered as statistically significant.During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively.The number of circulating EPMs independently predicted all-cause mortality (OR = 1.58; 95% CI = 1.20 - 1.88; P = 0.001), CHF-related death (OR = 1.22; 95% CI: 1.12 - 1.36; P < 0.001), and CHF-related re-hospitalization (OR = 1.20; 95% CI: 1.11 - 1.32; P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: State Medical University, Internal Medicine Department, Zaporozhye, Ukraine.

ABSTRACT

Background: Endothelial-derived apoptotic microparticles (EMPs) play a pivotal role in endothelial dysfunction in hronic Heart Failure (CHF).

Objectives: The present study aimed to evaluate the association between EMPs and pro-inflammatory biomarkers, clinical status, and outcomes in the patients with ischemic CHF.

Patients and methods: This study was conducted on 154 patients with ischemic symptomatic moderate-to-severe CHF on discharge from hospital. The observation period was up to 3 years. Circulating NT-pro-BNP, TNF-alpha, sFas, and sFas ligand were determined at baseline. Flow cytometry analysis was used for quantifying the number of EMPs. All-cause mortality, CHF-related death, and CHD-re-hospitalization rate were examined. The data were analyzed using descriptive statistics, Receive Operation Characteristic Curve (ROC), and logistic regression analysis. Besides, P < 0.05 was considered as statistically significant.

Results: During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively. The results showed a significant difference between the patients with a large number of EMPs (> 0.514 n/mL) and those with a low level of the biomarker (< 0.514 n/mL) regarding their survival. The number of circulating EPMs independently predicted all-cause mortality (OR = 1.58; 95% CI = 1.20 - 1.88; P = 0.001), CHF-related death (OR = 1.22; 95% CI: 1.12 - 1.36; P < 0.001), and CHF-related re-hospitalization (OR = 1.20; 95% CI: 1.11 - 1.32; P < 0.001).

Conclusions: Among the patients with symptoms of CHF, increased number of circulating EMPs was associated with increased 3-year CHF-related death, all-cause mortality, and risk of recurrent hospitalization due to CHF.

No MeSH data available.


Related in: MedlinePlus